Skip to Main Content

Eight years ago, a Dutch oncologist, John Haanen, set out to change melanoma treatment by arranging one of the largest and most rigorous trials ever for a cell therapy technique originally devised in the mid-’80s. He could not have picked worse timing.

Months after the trial began, European regulators approved the first PD-1 inhibitor, a groundbreaking immunotherapy. Patients clamored for it. “We had to wait,” Haanen said. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment